EP300 and prostate carcinoma: Furthermore, P300 as a transcriptional coactivator and histone acetyltransferases has been proved to involve in several pathological processes, and targeting P300 and thereby inhibiting subsequent downstream oncogenes is emerging as an efficient therapy intervention in several cancers including prostate cancer,59 hepatic cancer,60 cervical cancer,61 glioblastoma62 and ovarian cancer.63